Aquestive Therapeutics (AQST) Competitors

$4.22 +0.06 (+1.32%)

Closing price 03:59 PM Eastern

Extended Trading

$4.22 0.00 (0.00%)

As of 04:10 PM Eastern

AQST vs. ADPT, BHC, GENB, OCUL, and TRVI

Should you buy Aquestive Therapeutics stock or one of its competitors? MarketBeat compares Aquestive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aquestive Therapeutics include Adaptive Biotechnologies (ADPT), Bausch Health Cos (BHC), Generate Biomedicines (GENB), Ocular Therapeutix (OCUL), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

How does Aquestive Therapeutics compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Aquestive Therapeutics (NASDAQ:AQST) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Adaptive Biotechnologies has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Adaptive Biotechnologies presently has a consensus price target of $19.57, suggesting a potential upside of 40.92%. Aquestive Therapeutics has a consensus price target of $8.80, suggesting a potential upside of 108.28%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Adaptive Biotechnologies has higher revenue and earnings than Aquestive Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	8.02	-$59.50M	-$0.33	N/A
Aquestive Therapeutics	$44.54M	11.90	-$83.78M	-$0.61	N/A

In the previous week, Aquestive Therapeutics had 6 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Aquestive Therapeutics and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.44 beat Aquestive Therapeutics' score of -0.35 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adaptive Biotechnologies has a net margin of -16.82% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

Adaptive Biotechnologies beats Aquestive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Bausch Health Cos?

Aquestive Therapeutics (NASDAQ:AQST) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Bausch Health Cos has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.90	-$83.78M	-$0.61	N/A
Bausch Health Cos	$10.27B	0.20	$157M	-$3.24	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bausch Health Cos had 11 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 22 mentions for Bausch Health Cos and 11 mentions for Aquestive Therapeutics. Bausch Health Cos' average media sentiment score of 0.02 beat Aquestive Therapeutics' score of -0.35 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	4 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics presently has a consensus price target of $8.80, suggesting a potential upside of 108.28%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 46.39%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aquestive Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Aquestive Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Bausch Health Cos has a net margin of -11.47% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Summary

Bausch Health Cos beats Aquestive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Generate Biomedicines?

Aquestive Therapeutics (NASDAQ:AQST) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Aquestive Therapeutics currently has a consensus target price of $8.80, indicating a potential upside of 108.28%. Generate Biomedicines has a consensus target price of $25.40, indicating a potential upside of 81.34%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 10 more articles in the media than Generate Biomedicines. MarketBeat recorded 11 mentions for Aquestive Therapeutics and 1 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.27 beat Aquestive Therapeutics' score of -0.35 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has lower revenue, but higher earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.90	-$83.78M	-$0.61	N/A
Generate Biomedicines	$30.30M	59.26	N/A	N/A	N/A

Summary

Aquestive Therapeutics beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Aquestive Therapeutics has a net margin of -137.08% compared to Ocular Therapeutix's net margin of -558.24%. Aquestive Therapeutics' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Ocular Therapeutix presently has a consensus price target of $23.78, indicating a potential upside of 189.06%. Aquestive Therapeutics has a consensus price target of $8.80, indicating a potential upside of 108.28%. Given Ocular Therapeutix's higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Aquestive Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	34.67	-$265.94M	-$1.46	N/A
Aquestive Therapeutics	$44.54M	11.90	-$83.78M	-$0.61	N/A

In the previous week, Aquestive Therapeutics had 9 more articles in the media than Ocular Therapeutix. MarketBeat recorded 11 mentions for Aquestive Therapeutics and 2 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.00 beat Aquestive Therapeutics' score of -0.35 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aquestive Therapeutics beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Trevi Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Trevi Therapeutics	N/A	-24.53%	-23.37%

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Trevi Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.90	-$83.78M	-$0.61	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

In the previous week, Aquestive Therapeutics had 7 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Aquestive Therapeutics and 4 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.00 beat Aquestive Therapeutics' score of -0.35 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics currently has a consensus target price of $8.80, suggesting a potential upside of 108.28%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 61.61%. Given Aquestive Therapeutics' higher probable upside, equities research analysts clearly believe Aquestive Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Aquestive Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Summary

Trevi Therapeutics beats Aquestive Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$530.03M	$3.02B	$6.34B	$12.28B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	-6.93	17.79	20.92	25.48
Price / Sales	11.90	253.34	521.15	73.33
Price / Cash	N/A	56.99	43.18	55.00
Price / Book	-15.65	4.58	9.98	7.01
Net Income	-$83.78M	$74.99M	$3.55B	$335.16M
7 Day Performance	-10.68%	-2.46%	0.40%	-0.30%
1 Month Performance	-2.65%	-4.23%	-0.04%	1.14%
1 Year Performance	86.12%	36.32%	34.95%	34.69%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	2.4497 of 5 stars	$4.23 +1.3%	$8.80 +108.3%	+74.5%	$530.03M	$44.54M	N/A	160	Analyst Revision
ADPT Adaptive Biotechnologies	3.3711 of 5 stars	$13.01 -1.3%	$19.57 +50.5%	+49.1%	$2.08B	$276.98M	N/A	790
BHC Bausch Health Cos	2.8305 of 5 stars	$5.39 -1.2%	$8.00 +48.6%	+17.9%	$2.01B	$10.27B	N/A	20,300	Trending News Insider Trade Analyst Revision
GENB Generate Biomedicines	N/A	$15.69 +1.4%	$25.40 +61.9%	N/A	$2.01B	$30.30M	N/A	312	Gap Up
OCUL Ocular Therapeutix	2.4414 of 5 stars	$9.18 -3.4%	$23.78 +159.2%	+5.7%	$2.01B	$51.95M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. ADPT, BHC, GENB, OCUL, and TRVI

How does Aquestive Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Aquestive Therapeutics compare to Bausch Health Cos?

Summary

How does Aquestive Therapeutics compare to Generate Biomedicines?

Summary

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Summary

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. ADPT, BHC, GENB, OCUL, and TRVI

How does Aquestive Therapeutics compare to Adaptive Biotechnologies?

Which has more volatility and risk, ADPT or AQST?

Do analysts recommend ADPT or AQST?

Do institutionals & insiders hold more shares of ADPT or AQST?

Which has higher valuation and earnings, ADPT or AQST?

Does the media prefer ADPT or AQST?

Is ADPT or AQST more profitable?

Summary

How does Aquestive Therapeutics compare to Bausch Health Cos?

Which has better earnings and valuation, AQST or BHC?

Do institutionals & insiders have more ownership in AQST or BHC?

Does the media refer more to AQST or BHC?

Do analysts rate AQST or BHC?

Which has more risk & volatility, AQST or BHC?

Is AQST or BHC more profitable?

Summary

How does Aquestive Therapeutics compare to Generate Biomedicines?

Do analysts prefer AQST or GENB?

Do insiders and institutionals hold more shares of AQST or GENB?

Does the media prefer AQST or GENB?

Is AQST or GENB more profitable?

Which has higher valuation and earnings, AQST or GENB?

Summary

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Is OCUL or AQST more profitable?

Which has more risk and volatility, OCUL or AQST?

Do analysts prefer OCUL or AQST?

Which has preferable earnings & valuation, OCUL or AQST?

Does the media refer more to OCUL or AQST?

Do insiders & institutionals hold more shares of OCUL or AQST?

Summary

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Is AQST or TRVI more profitable?

Do institutionals and insiders hold more shares of AQST or TRVI?

Which has preferable valuation and earnings, AQST or TRVI?

Does the media refer more to AQST or TRVI?

Do analysts recommend AQST or TRVI?

Which has more volatility & risk, AQST or TRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools